Dr. Sarah Tabrizi is Director of the UCL Huntington’s Disease Centre and Joint-Head of the Department of Neurodegenerative Disease, at the UCL Queen Square Institute of Neurology. Sarah’s multidisciplinary research…
Charles Sabine Tedx BATH Talk
Charles Sabine is part of our HD community and delivered an outstanding Tedx Talk on his experience with Huntington's disease. Check out: The Unlimited Capability of Every Human | Charles…
Unravelling the role of huntingtin: from neurodevelopment to neurodegeneration
The journal, Brain, highlights a recent paper on "Genetic topography and cortical cell loss in Huntington's disease link development and neurodegeneration". A review by Schultz et al., succinctly summarizes intriguing…
Amazing year for the UCI Sue and Bill Gross Stem Cell Research Center!
HD-CARE supports the UCI Thompson Lab, which is located in the UCI Sue and Bill Gross Stem Cell Research Center (SCRC). The SCRC thanked us for making 2023 an incredible…
Huntington Study Group® and Roche Collaborate on Generation HD2 Study
Exciting new collaboration between the Huntington's Study Group (HSG) and Roche therapeutics. HSG will advise Roche on recruitment and enrollment of the needs of GENERATION HD2. This work will collectively…
SAGE Therapeutics announces FDA approved drug for HD cognitive therapy
SAGE therapeutics is a biopharmaceutical company with the mission of improving brain health. On 11/13/23, SAGE announcted that the US Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD)…
New FDA Approved Drug for Chorea
The Huntington Study Group (HSG) shared that the Phase 3 KINECT-HD study resulted in FDA approval of valbenazine for treatment of chorea in Huntington's disease (HD). As a vesicular monoamine…
Join us for Sounds of the Bayou!
Register today! HD-Care invites you to our summer fundraiser on Saturday September 30, 2023 1-4pm at Campus Jax. Live music and "Live Ask" opportunity to support HD research and patient…
Thanks to UCI MIND for highlighting our 10 years of hard work!
In the UCI MIND quarterly newsletter, HD-CARE is celebrated as 10 years as a non-profit organization! Check out the article along with other exciting news from UCI: https://mind.uci.edu/mind-matters-quarterly-newsletter-winter-2023/
Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington’s Disease
From Huntington Study Group: Prilenia Therapeutics B.V., a clinical stage biotechnology company, met a milestone that the last participant in PROOF-HD, a global Phase 3 study in Huntington’s disease (HD),…